TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32109880
Drug: Late bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late bolus carbohydrate ingestion (1 × 75 g after 75 min)
Study: 35304280
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide
Study: 34560906
Drug: Ixekizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (both dosing regimens)
Study: 35931598
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine (PI) disinfecting solution
Study: 34625041
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (AL) 1064 mg q8wk
Study: 34625041
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) 156 mg q4wk
Study: 34117400
Drug: Single site
Normalized name: Seprafilm Single Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single site phacotrabeculectomy with MMC 0.2 mg/mL
Study: 34117400
Drug: Twin-site phacotrabeculectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twin-site phacotrabeculectomy with MMC 0.2 mg/mL
Study: 34076495
Drug: Pluchea indica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pluchea indica tea (PIT) 1.5g once daily for 12 weeks
Study: 34076495
Drug: Camellia sinensis
Normalized name: Camellia Sinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camellia sinensis tea (CST) 1.5g once daily for 12 weeks
Study: 33377218
Drug: Inhaled nebulised
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulised unfractionated heparin (UFH)
Study: 32270637
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with opioid drugs (Oxycodone hydrochloride prolonged-release tablet)
Study: 32270637
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride prolonged-release tablet (Control group)
Study: 33547453
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to online misinformation about COVID-19 vaccines
Study: 33547453
Drug: Factual information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factual information about COVID-19 vaccines
Study: 32652432
Drug: Magnetic resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic resonance enterography and colonography (MREC) with water enema and intravenous spasmolytics
Study: 36397216
Drug: Huayu Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huayu Tongluo moxibustion combined with intradermal needling (6 times a week for 4 weeks)
Study: 36397216
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (paroxetine hydrochloride tablets, 20 mg once daily for 4 weeks, max 40 mg/d)
Study: 36067489
Drug: Macleaya cordata
Normalized name: Tilia cordata pollen
DrugBank: Tilia cordata pollen (DB10954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macleaya cordata extract (MCE) at 100 mg/kg
Study: 33864634
Drug: Octanoic acid
Normalized name: Octanoic acid
DrugBank: Caprylic acid (DB04519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octanoic acid (OA) treatment over a 2-week period
Study: 32151101
Drug: Bite splint
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bite splint + Platelet-rich plasma injection
Study: 32151101
Drug: Bite splint
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bite splint + Sodium hyaluronate injection
Study: 32151101
Drug: Bite splint
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bite splint + Betamethasone injection
Study: 35807872
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (CF) 790 mg
Study: 33430841
Drug: KalobaTUSS® syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: KalobaTUSS® syrup
Study: 36148830
Drug: 4L single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4L single dose polyethylene glycol (PEG) given in the evening before
Study: 36148830
Drug: 4L split-dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4L split-dose PEG
Study: 36148830
Drug: 2L split-dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L split-dose PEG (+ bisacodyl 15 mg)
Study: 36148830
Drug: 2L single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L single dose PEG (+ bisacodyl 15 mg) in the morning
Study: 32068975
Drug: 6-month intervention
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month intervention consisting of 2 hours of physical exercise, cognitive training, and classroom study or rest once weekly
Study: 34837758
Drug: Group Acceptance
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Acceptance and Commitment Therapy (G‐ACT)
Study: 32917192
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide gel
Study: 35537858
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 20 mg/kg/d, b.i.d. for 4 weeks
Study: 35724828
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/day) and Zinc (15 mg/day)
Study: 35724828
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment with Doxycycline
Study: 35288227
Drug: Postoperative irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative irradiation plus adjuvant systemic therapy
Study: 35288227
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic therapy alone
Study: 33673616
Drug: Melatonin rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin rinse solution
Study: 33673616
Drug: Placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rinse solution
Study: 33546733
Drug: AANmDOF robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AANmDOF robotic training (combination of training in LOPES‐II and conventional gait training, 30 min, 3–5 times a week for 6 weeks)
Study: 36078940
Drug: 4.4 MHz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 MHz Radiofrequency (RF) therapy
Study: 37079158
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake estimated from 24‐h urinary iodine excretion (UIE)
Study: 37079158
Drug: Contribution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contribution of discretionary salt to daily iodine intake
Study: 34229267
Drug: Mixed oil
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed oil intravenous lipid emulsion (MO ILE)
Study: 34229267
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil intravenous lipid emulsion (SO ILE)
Study: 39040578
Drug: Brensocatib 10
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 10 mg
Study: 39040578
Drug: Brensocatib 25
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 25 mg
Study: 35411669
Drug: Brensocatib 40
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 40 mg
Study: 35411669
Drug: Brensocatib 40
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 40 mg (with food)
Study: 35411669
Drug: Brensocatib 40
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 40 mg (without food)
Study: 33832949
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg once daily from day 1 to 14 every 3 weeks)
Study: 32933755
Drug: hs‐cTnT peak
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs‐cTnT peak value <3,500 ng/L
Study: 34318438
Drug: Scheduled oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled oral regimen of ibuprofen plus acetaminophen (alternating every 3 hours or concurrent every 6 hours for 5 days)
Study: 34318438
Drug: HTX-011 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (300 mg bupivacaine/9 mg meloxicam)
Study: 34318438
Drug: HTX-011 with
Normalized name: Human papillomavirus virus-like particles conjugated with ir700 dye au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 with ibuprofen/acetaminophen
Study: 33576284
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity prescription (PAP)
Study: 32828187
Drug: Community engagement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community engagement and community health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with hypertension.
Study: 33433847
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (40 mL twice a day for a week)
Study: 33433847
Drug: Statins intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins intensive group (atorvastatin 80 mg once, then 40 mg daily for 1 week)
Study: 33433847
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (atorvastatin 10–20 mg daily for 1 week)
Study: 33726903
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg or 30 mg once daily)
Study: 33661141
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (0.05 μg·kg‐1·min‐1) for 30 min before spinal anesthesia
Study: 33661141
Drug: Ephedrine bolus
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine bolus (0.15 mg/kg) before spinal anesthesia
Study: 35398908
Drug: Music-only condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-only condition (sham treatment)
Study: 32054731
Drug: Acalabrutinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 200 mg once daily
Study: 35921114
Drug: 195 mg
Normalized name: aspirin 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 195 mg transdermal cannabidiol
Study: 35921114
Drug: 390 mg
Normalized name: kaolin 390 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 390 mg transdermal cannabidiol
Study: 34467639
Drug: Early-food supplementation
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-food supplementation (daily supplementation starting before 9 gestation weeks)
Study: 34467639
Drug: Usual-food supplementation
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-food supplementation (daily supplementation starting at 20 gestation weeks)
Study: 34467639
Drug: Prenatal supplementation
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal supplementation with 30-mg or 60-mg iron with 400-µg folic acid or multiple micronutrients (MM)
Study: 33009977
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet (ELENTAL®) 160 g/day for 9 weeks during chemotherapy
Study: 32631405
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A 25,000 IU daily, Vitamin D 600,000 IU once, Vitamin E 300 IU twice daily, Vitamin C four times per day, B vitamins daily (Soluvit)
Study: 32631405
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplements or placebo)
Study: 32100495
Drug: Suspension moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension moxibustion combined with hormone therapy
Study: 32100495
Drug: Hormone without
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone without moxibustion
Study: 32100495
Drug: Hormone with
Normalized name: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone with moxibustion
Study: 34687130
Drug: High M6-GGT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High M6-GGT levels (>25 U/L)
Study: 34687130
Drug: High M6-GGT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High M6-GGT levels (>25 U/L) in non-cirrhotic patients
Study: 35487727
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg alirocumab subcutaneously every 2 weeks for a total of 26 weeks
Study: 35487727
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no alirocumab treatment)
Study: 35081022
Drug: High-dose convalescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose convalescent plasma (CCP) transfusion (3 daily doses of 600 mL/d)
Study: 35081022
Drug: High-dose convalescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose convalescent plasma (CCP) transfusion
Study: 33237632
Drug: POG patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: POG patients with WGTA-informed treatment change
Study: 33764385
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (molecular inhibitor)
Study: 33764385
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (cytotoxic therapy)
Study: 33764385
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (hormone therapy)
Study: 33764385
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (immune therapy)
Study: 35727083
Drug: Esketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.5 mg/kg parenteral dose)
Study: 34229074
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine intravenous infusion
Study: 34229074
Drug: Simultaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous morphine + naloxone infusion
Study: 32385061
Drug: PIFR-based optimised
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIFR-based optimised inhalation therapy and training on inhaler usage at discharge
Study: 33742764
Drug: RO6870868 (200–2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6870868 (200–2000 mg)
Study: 35673907
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) + chemotherapy
Study: 32942192
Drug: Contact intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact intervention for parents with supervised contact, involving increased preparation and support by caseworkers before and after contact visits
Study: 35133982
Drug: Paclitaxel chemotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel chemotherapy
Study: 33551142
Drug: Flapless implant
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flapless implant placement with immediate functional loading
Study: 33551142
Drug: Flap implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap implant placement with immediate functional loading
Study: 35446296
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioral therapy (TF-CBT) for 14 weeks with 2 weeks follow-up
Study: 32253054
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 320/36/9.6 μg without spacer and no charcoal
Study: 32253054
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 320/36/9.6 μg with spacer and no charcoal
Study: 32253054
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 320/36/9.6 μg without spacer and with charcoal
Study: 32253054
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 320/36/9.6 μg with spacer and with charcoal
Study: 34711975
Drug: Undisclosed self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undisclosed self-administration of suboptimal ART
Study: 35448022
Drug: Traditional Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Cognitive Rehabilitation Group (TCRG) received standard cognitive treatment
Study: 33128925
Drug: Cold-dry conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-dry conditions (CC, −20 °C, RH 40%)
Study: 33593749
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg, orally, once daily for 24 weeks
Study: 33593749
Drug: Pioglitazone 15-30
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15-30 mg, orally, once daily for 24 weeks
Study: 35667714
Drug: Investigational agents
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational agents (up to four agents)
Study: 32114088
Drug: Vaccine blog
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine blog posts
Study: 34018624
Drug: Randomization-based inference
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization-based inference for a marginal treatment effect in SWTs
Study: 35872928
Drug: Acupotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupotomy and electroacupuncture therapy
Study: 35872928
Drug: Hot compress,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot compress, oral medication, and local injection
Study: 33645201
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone 1‐34 alone (Group A)
Study: 33645201
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone 1‐34 plus Zoledronic Acid (ZA) (Group B)
Study: 33482681
Drug: Prophylactic doses
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic doses of novel direct oral anticoagulants (DOACs)
Study: 33541274
Drug: Colistin-based combination
Normalized name: colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistin-based combination therapy
Study: 35931948
Drug: Median nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median nerve block (5 ml of 0.5% lidocaine)
Study: 35931948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (subcutaneous local block)
Study: 32866837
Drug: 10% imidacloprid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% imidacloprid + 2.5% moxidectin (topical once monthly for 9 months) and doxycycline (10 mg/kg twice daily for 28 days)
Study: 32866837
Drug: Melarsomine dihydrochloride
Normalized name: melarsomine dihydrochloride
DrugBank: Melarsomine (DB11528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melarsomine dihydrochloride (2.5 mg/kg, two injections 24 hours apart)
Study: 35101883
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (in subgroup with PD-L1 expression ≥50%)
Study: 35101883
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (in subgroup with PD-L1 expression ≥50%)
Study: 35322711
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D supplementation (50,000 IU on the first day followed by 10,000 IU/day for 29 days)
Study: 35322711
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 1000 IU vitamin D daily and a placebo soft gel
Study: 33485328
Drug: Opioid-free perioperative
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free perioperative analgesic pathway
Study: 33485328
Drug: Traditional opioid-including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional opioid-including perioperative medications
Study: 36915205
Drug: ENG‐IMPLANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENG‐IMPLANT
Study: 36915205
Drug: DSG + ENG‐IMPLANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSG + ENG‐IMPLANT
Study: 33476534
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate injection (5 mg/kg) at 1 hour before ventilator weaning
Study: 33476534
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with caffeine
Study: 32314327
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of non-resectable, non-ablatable CLM